{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-22-000109","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2022-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.356375+00:00","generated_at":"2026-06-23T05:58:17.045925+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Summit Therapeutics appoints Dr. Robert Booth to Board of Directors; Dr. Urte Gayko resigns from Board","bullets":["Dr. Robert Booth appointed to Board effective September 28, 2022; will join Nominating and Corporate Governance Committee.","Dr. Booth initiated the BTK inhibitor program at Celera Genomics that led to Pharmacyclics' blockbuster drug Imbruvica (ibrutinib).","Dr. Booth received stock option grant per non-employee director compensation policy and standard indemnification agreement.","Dr. Urte Gayko resigned from Board to focus on her full-time role as Head of Regulatory, Safety, and Quality; resignation not due to any disagreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-22-000109","json":"https://secwatch.observer/filing/0001599298-22-000109.json","markdown":"https://secwatch.observer/filing/0001599298-22-000109.md","text":"https://secwatch.observer/filing/0001599298-22-000109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/0001599298-22-000109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/smmt-20220928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:58:17.045925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d63e403b1","claim":"Urte Gayko resigned as Director at Summit Therapeutics Inc..","evidence_excerpt":"effective September 28, 2022, Urte Gayko resigned from the Board of the Company in order to create a vacancy for Dr. Robert Booth, PhD","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/0001599298-22-000109-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6d3cf58b08","claim":"Robert Booth was appointed as Director at Summit Therapeutics Inc..","evidence_excerpt":"On September 28, 2022, the Board unanimously approved (i) the election of Dr. Robert Booth, PhD as a director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/0001599298-22-000109-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}